Affiliation:
1. Research Department, F. Hoffmann-La Roche & Co. Ltd., Basle, Switzerland
Abstract
Abstract
In rats, a combination of small doses of the dopa decarboxylase inhibitor Ro 4–4602 [N-(DL-seryl)-N’-(2,3,4-trihydroxybenzyl)hydrazine] with dopa causes a marked enhancement of the spontaneous locomotor activity which is not seen with dopa alone. If high instead of low doses of Ro 4–4602 are used, locomotor stimulation does not occur. Low doses of Ro 4–4602, owing to selective inhibition of extracerebral decarboxylase, enhance the dopa-induced rise of dopa and catecholamines in the brain, whereas high doses of Ro 4–4602, which also inhibit the cerebral dopa decarboxylase, increase only the level of dopa but not that of the catecholamines. It is concluded that the locomotor activation after small doses of Ro 4–4602 in combination with dopa is due to cerebral accumulation of catecholamines which consist mainly of dopamine.
Publisher
Oxford University Press (OUP)
Subject
Pharmaceutical Science,Pharmacology
Cited by
82 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献